EUCTR2006-006449-14-DE进行中（未招募）不适用
Multicenter, Double-Blind, Randomized, Controlled, Parallel Comparison of Efficacy and Safety of Fixed Doses of Two Formulations of Botulinum Toxin Type A in the Treatment of Moderate to Severe Cervical Dystonia (BOTOX® 200 Units and Dysport® 750 Units)
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects with idiopathic cervical dystonia of the predominantly rotational form (i.e., spasmodic torticollis) of minimum duration eighteen (18) months.
- •2. Moderate-to-severe symptoms as defined by a minimum Toronto Western Spasmodic Torticollis Scale (TWSTRS) severity scale score of 15, with a rotation score >2 and a duration factor >2.
- •3. Subjects have received successful treatment as determined clinically by both the investigator and patient with 180 – 220 U BOTOX® in each of the last two (2) treatment sessions.
- •4. Cervical dystonia symptom severity is considered predictable and successfully responsive to BOTOX® treatment.
- •5. The most recent treatment with BOTOX® occurred on a date at least 16 weeks prior to study entry, and the subject has received two (2) treatment sessions within the prior 40 weeks with a good clinical response.
- •6. Outpatient, male or female subjects, of any race, age 18 and older.
- •7. Screening laboratory values either within the reference ranges as defined by the laboratory or in the investigator’s opinion out of range test results that are not clinically significant.
- •8. Negative urine pregnancy test on the day of treatment prior to the administration of study medication (for female subjects of childbearing potential).
- •9. Written informed consent has been obtained.
- •10. Written Authorization for Use and Release of Health and Research Study Information (as applicable) has been obtained.
- •11. Written Data Protection Consent (European and Indian sites only) has been obtained.
- •12. Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable.
- •13. Ability to follow study instructions and likely to complete all required visits.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Symptomatic or non-idiopathic cervical dystonia.
- •2. Current or previous surgery, peripheral denervation, and/or spinal cord stimulation for the management of cervical dystonia.
- •3. Previous injections of phenol or alcohol for cervical dystonia.
- •4. History or evidence of secondary non-response to botulinum toxin type A therapy.
- •5. Presence of significant anterocollis, retrocollis, or head shift as the principal component of cervical dystonia.
- •6. Profound atrophy of the muscles in the target area(s) of injection.
- •7. Infection or skin problem at the anticipated injection site.
- •8. Myasthenia Gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis or any other disease that might interfere with neuromuscular function.
- •9. Current anticoagulant therapy.
- •10. Failure to meet prohibited/restricted concomitant medication criteria:
- •11. Subjects planning inpatient surgery or other elective hospitalization during the study period.
- •12. Females who are pregnant, nursing, or planning a pregnancy (positive urine pregnancy test).
- •13. Females of childbearing potential, not using a reliable means of contraception.
- •14. Any uncontrolled systemic disease.
- •15. History of treatment with botulinum toxin type A of any brand other than BOTOX® within the past two (2) years.
- •16. History of treatment with botulinum toxin type B within the past two (2) years.
- •17. Allergy or sensitivity to any component of the study medication.
- •18. Recent history of alcohol or drug abuse (as defined by DSM IV criteria).
- •19. History of poor cooperation, non-compliance with medical treatment, or unreliability.
- •20. Subjects currently participating in another investigational drug study or who have participated in an investigational drug study within 30 days of the Baseline Visit.
- •21. Any condition or situation which, in the investigator’s opinion, places the patient at significant risk, could confound the study results, or may interfere significantly with the patient’s participation in the study.
研究者
相似试验
进行中（未招募）
1 期
Study into the safety and efficacy of eczema cream Clobetasone Butyrate.EUCTR2015-004899-30-Outside-EU/EEAGlaxoSmithKline Research & Development Ltd.240
已完成
不适用
Multi-center, Randomized, Double blind, Controlled Parallel-group Comparative Phase 3 Clinical trial to assess the efficacy and safety of Propacetamol Compared to Dexibuprofen in patients with Acute upper respiratory tract infectioKCT0002888Yungjin Pharm322
尚未招募
1 期
Randomized, controlled, double-blind, multicenter, prospective clinical study and mechanism exploration of Qinggan Sanjie Xiaoying Decoction in treating Hashimoto's thyroiditisHashimoto's thyroiditisITMCTR2200006524Sun Simiao Hospital of Beijing University of traditional Chinese Medicine
未知
3 期
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's DiseaseSevere Alzheimer's Type DementiaJPRN-jRCT2080221731Eisai Co., Ltd.330
进行中（未招募）
不适用
TLG-001J Confirmatory Clinical TrialMyopiaJPRN-jRCT2032220217Tsubota Kazuo160